AYTU BIOPHARMA, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on May 11, 2016, by Aytu BioScience, Inc. (also referenced as AYTU BIOPHARMA, INC in metadata). The report discloses the issuance of a press release announcing financial results for the quarter ended March 31, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves solely as a notification that the quarterly results have been announced via a press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q1 2016 financial figures.
- Verify the company's current name usage, as the filing header lists "AYTU BIOSCIENCE, INC" while metadata references "AYTU BIOPHARMA, INC".
- Confirm the exact date of the press release (May 11, 2016) to ensure alignment with the reporting period ended March 31, 2016.